AI-generated analysis. Always verify with the original filing.
NextCure, Inc. reported full year 2025 financial results, including a net loss of $55.8 million and cash position of $41.8 million as of December 31, 2025, sufficient to fund operations into the first half of 2027. The company provided business updates on SIM0505 and LNCB74 clinical programs with key milestones anticipated in 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
(including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the ”Exchange Act”), o
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued by NextCure, Inc. dated March 5, 2026 104 Cover Page Intera
| Metric | Value | Basis |
|---|---|---|
| Research and development | $44.9K | GAAP |
| General and administrative | $12.7K | GAAP |
| Loss from operations | $-57.6K | GAAP |
| Net loss | $-55.8K | GAAP |
| Net loss per common share - basic and diluted | $-19.65 | GAAP |